China NMPA Inspection - Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. - June 22, 2021

On June 22, 2021, the Guangxi Zhuang Autonomous Region Drug Administration publicly announced the inspection results for 29 licensed cosmetics manufacturers operating within the region. These inspections were carried out as part of the 2021 regional cosmetics supervision work plan, aimed at strengthening oversight of the cosmetics manufacturing sector. The regulatory framework for these actions falls under the purview of the Guangxi Zhuang Autonomous Region Drug Administration, which operates under the broader authority of China's National Medical Products Administration (NMPA). While the announcement lists the names of all 29 companies, including prominent ones like Guangxi Fucodisai Regenerative Medicine Engineering Co., Ltd. and Beihai Haizhenzhu Cosmetics Co., Ltd., it does not detail specific violations or issues discovered during the inspections. The document indicates that detailed inspection results for each company are available in separate attachments. The purpose of this public disclosure is to inform stakeholders about the regulatory findings. Although not explicitly stated, such announcements typically imply that non-compliance or areas requiring improvement were identified, necessitating corrective actions from the inspected manufacturers to ensure adherence to cosmetic supervision standards. The administration's proactive approach highlights its commitment to maintaining product quality and safety within the regional cosmetics industry.